Key Notes
- OpenAI president Greg Brockman raised the possibility that AI-driven biological research could eventually make death a choice, without setting a date for that outcome.
- His nearer-term prediction concerns meaningful advances in biology, healthcare and treating diseases over the next twelve to eighteen months.
- Early AI-assisted drug research offers concrete examples of progress, but laboratory results still require clinical testing before they establish benefits for patients.
Death could eventually become a choice rather than an inevitability, according to Greg Brockman, co-founder and president of OpenAI. His latest prediction puts a sweeping ambition behind the industry’s push into biology: using increasingly capable AI systems to understand disease and help develop treatments that human researchers have struggled to find.
Speaking at WSJ Tech, Brockman raised the prospect of “death becoming a choice” while discussing suffering and biological discovery. In remarks published on November 5, he described that possibility as achievable. He also predicted meaningful advances in biology, health and treating diseases over the next 12–18 months.
The two claims have different time horizons. Brockman did not give a date for making death optional, and he acknowledged that delivering the full benefits of AI in life sciences would take time. His near-term forecast concerns progress against disease; the much larger claim about mortality remains a prediction.
The AI Race Is Moving Into the Laboratory
The comments come as OpenAI increasingly pitches its models as tools for scientific work alongside coding and office tasks. In the same conference appearance, Brockman discussed the company’s growing enterprise business and readiness for a possible 2027 IPO. Medicine offers a different test of that expansion: producing a useful hypothesis is only one step toward a treatment.
Rival Anthropic has already published examples of what that work can look like. Its October 27 research update described projects with six organizations developing medicines. The tasks extend beyond proposing molecules to improving their properties, organizing experiments and preparing manufacturing records.
In one project with Generate Biomedicines, scientists used Claude Code to redesign part of the genetic instructions for a CAR T-cell therapy. Anthropic said one design was about 70% shorter and performed better in laboratory tests, potentially leaving room for instructions aimed at treating solid tumors. Those are early experimental findings, rather than evidence that the approach has cured cancer in patients.
That distinction also runs through the expansion of Claude Science. The commercial opportunity is to make many stages of drug development more productive. Whether those improvements ultimately produce safe, effective medicines has to be established separately for each program.
A Faster Discovery Still Has to Survive Human Trials
The gap between a promising laboratory result and a proven treatment is substantial. The FDA’s clinical research guidance explains that preclinical work cannot substitute for studies of how a drug interacts with the human body. Trials examine dosage, side effects and treatment benefits in progressively larger groups.
The agency describes late-stage Phase 3 studies as typically lasting one to four years. AI may help design those studies, analyze results or identify better candidates before they begin, but a convincing computer-generated answer does not establish long-term safety. An advance announced within Brockman’s forecast window could therefore be important without immediately becoming an available medicine.
For now, the measurable questions are narrower than whether humanity can defeat death: Can AI-assisted programs produce better drug candidates, reduce failed experiments and deliver treatments that improve patients’ lives? Progress on those fronts would be consequential on its own. Brockman’s larger vision will need evidence far beyond a model’s ability to reason about biology.
Disclaimer: AIstify is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, technology, software, and digital innovation sectors. These relationships do not influence AIstify’s editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.
